Table 4.
Studies of stereotactic body radiotherapy for stage I non-small cell lung cancer
|
Author |
|
Dose* median follow-up |
3yLC |
3yOS |
|
|---|---|---|---|---|---|
| (reference) | n | (Gy) | (mo) | (%) | (%) |
| Onishi (2) |
257 |
30-84(i) |
38 |
NA |
57 |
| Timmerman (8) |
55 |
54(p) |
34 |
98 |
56 |
| Nagata (10) |
42 |
48(i) |
30 |
NA |
83 (T1 only) |
| Onimaru (21) |
41 |
40-48(i) |
27 |
57 |
47 |
| Uematsu (30) |
50 |
40-60(i) |
60 |
NA |
66 |
| Koto (31) |
31 |
45-60(i) |
32 |
78 |
72 |
| Nyman (32) |
45 |
45(p) |
43 |
80 |
55 |
| Takeda (33) |
38 |
50(p) |
31 |
93 (T1 only) |
90 (T1 only) |
| Taremi (34) |
108 |
48-60(p) |
19 |
89 (4y) |
30 (4y) |
| Current study | 109 | 48(i) or 40(p) | 25 | 81 | 68 |
*Dose was prescribed at the isocenter (i) or periphery (p) of the tumor.